The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions

Abstract

BackgroundRecent advances in understanding molecular and synaptic mechanisms of intellectual disabilities (ID) in fragile X syndrome (FXS) and Down syndrome (DS) through animal models have led to targeted controlled trials with pharmacological agents designed to normalize these underlying mechanisms and improve clinical outcomes. However, several human clinical trials have failed to demonstrate efficacy of these targeted treatments to improve surrogate behavioral endpoints. Because the ultimate index of disease modification in these disorders is amelioration of ID, the validation of cognitive measures for tracking treatment response is essential. Here, we present preliminary research to validate the National Institutes of Health Toolbox Cognitive Battery (NIH-TCB) for ID.MethodsWe completed three pilot studies of patients with FXS (total n = 63; mean age 19.3 ± 8.3 years, mean mental age 5.3 ± 1.6 years), DS (n = 47; mean age 16.1 ± 6.2, mean mental age 5.4 ± 2.0), and idiopathic ID (IID; n = 16; mean age 16.1 ± 5.0, mean mental age 6.6 ± 2.3) measuring processing speed, executive function, episodic memory, word/letter reading, receptive vocabulary, and working memory using the web-based NIH-TB-CB, addressing feasibility, test-retest reliability, construct validity, ecological validity, and syndrome differences and profiles.ResultsFeasibility was good to excellent (≥80 % of participants with valid scores) for above mental age 4 years for all tests except list sorting (working memory). Test-retest stability was good to excellent, and convergent validity was similar to or better than results obtained from typically developing children in the normal sample for executive function and language measures. Examination of ecological validity revealed moderate to very strong correlations between the NIH-TCB composite and adaptive behavior and full-scale IQ measures. Syndrome/group comparisons demonstrated significant deficits for the FXS and DS groups relative to IID on attention and inhibitory control, a significant reading weakness for FXS, and a receptive vocabulary weakness for DS.ConclusionsThe NIH-TCB has potential for assessing important dimensions of cognition in persons with ID, and several tests may be useful for tracking response to intervention. However, more extensive psychometric studies, evaluation of the NIH-TCB’s sensitivity to change, both developmentally and in the context of treatment, and perhaps establishing links to brain function in these populations, are required to determine the true utility of the battery as a set of outcome measures.

The NIH Toolbox for cognitive surveillance in Duchenne muscular dystrophy

“…The NIH Toolbox is a scientifically rigorous, multidimensional measure designed to bring uniformity to evaluation of neurological function across the life span . The NIHTB‐CB tests have previously been evaluated for their reliability, validity, and other psychometric properties, including among individuals with several different neurodevelopmental disorders . We hypothesized that the NIHTB‐CB would be sensitive to detect cognitive deficits in domains known to be impaired in DMD.…”

Evaluating Social Interactions Using the Autism Screening Instrument for Education Planning-3rd Edition (ASIEP-3): Interaction Assessment in Children and Adults with Fragile X Syndrome

“…The CDC FORWARD Component-C projects (RFA# U01DD001190) were funded with the goal of evaluating new outcome measures in FXS and documenting the longitudinal trajectory of FXS cognitive and behavioral profiles over one's lifespan. Progress has been made over the past 5 years in the Fragile X field by evaluating more objective outcome measures that do not involve parental reporting, including measures of attention [40], expressive language [41,42], and executive functioning [43,44]. Eye tracking technology has been used to examine aspects of social attention while viewing videos [45,46], as well as in a naturalistic setting [47].…”

Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments

“…51 FMRP is an RNA-binding protein involved in the regulation of hundreds of mRNAs in postsynaptic neurons, typically through inhibition. To date, clinical trials for FXS have had only limited success; however, current research in the IDDRC network is focused on developing new outcome measures 60 and clinical trial designs, including combining a parentimplemented behavioral intervention and a selective mGluR antagonist. 52,53 Early work by IDDRC scientists describing the emergence of the behavioral phenotype in humans, documented a declining rate of cognitive development and a variety of comorbid symptoms.…”